Autoantibody profiles as biomarkers for response to therapy and early detection of cancer

Current Cancer Therapy Reviews

Volumn 4, Issue 2, 2008, Pages 149-156

  Kalnina, Zane ^a   Silina, Karina ^a   Line, Aija ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

Author keywords

Antigen microarray; Autoantibodies; Early detection; Response to immunotherapy; Tumour associated antigens

Indexed keywords

EID: 54749087862     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408784310160     Document Type: Review

References (93)

1. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens molecular definition and implications. Mol Med Today 1997; 3: 342-9.
2. Barua A, Bradaric MJ, Kebede T, et al. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol 2007; 57: 243-9.
3. Ehlken H, Schadendorf D, Eichmuller S. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 2004; 108: 307-13.
4. Nesslinger NJ, Sahota RA, Stone B; et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007; 13: 1493-502.
5. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [see comments]. J Exp Med 1998; 187: 1349-54.
6. Zhang JY. Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 2004; 28: 114-8.
7. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60: 1777-88.
8. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 136-43.
9. Scanlan MJ, Gout I, Gordon CM, et al. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001; 1: 4.
10. Ludewig B, Krebs P, Metters H, Tatzel J, Tureci O, Sahin U. Molecular characterization of virus-induced autoantibody responses. J Exp Med 2004; 200: 637-46.
11. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 4041-7.
12. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003; 9: 5120-6.
13. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudemack G, Smeland EB. Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004; 53: 431-8.
14. Zhong L, Peng X, Hidalgo GE, Doherty DE, Stromberg AJ, Hirschowitz EA. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004; 4: 1216-25.
15. Wadle A, Mischo A, Imig J, et al. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 2005; 117: 104-13.
16. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 2001; 1: 890-8.
17. Philip R, Murthy S, Krakover J, et al. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res 2007; 6: 2509-17.
18. Qin S, Qiu W, Ehrlich JR, et al. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 2006; 6: 3199-209.
19. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004; 3: 261-7.
20. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66: 1181-90.
21. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-35.
22. Fernandez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer. Cancer Res 2004; 64: 5089-96.
23. Bouwman K, Qiu J, Zhou H, et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003; 3: 2200-7.
24. Mischo A, Wadle A, Watzig K, et al. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immmun 2003; 3: 5.
25. Hansen MH, Ostenstad B, Sioud M. Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumour. Int J Oncol 2001; 19: 1303-9.
26. Pavoni E, Vaccaro P, Pucci A, et al. Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage. BMC Cancer 2004; 4: 78.
27. Lichtenfels R, Kellner R, Atkins D, et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim Biophys Acta 2003; 1646: 21-31.
28. Yang F, Xiao ZQ, Zhang XZ, et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007; 6: 751-8.
29. Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous carcinoma. Proteomics 2006; 6: 547-58.
30. Hardouin J, Lasserre JP, Canelle L, et al. Usefulness of autoantigens depletion to detect autoantibody signatures by multiple affinity protein profiling. J Sep Sci 2007; 30: 352-8.
31. Zhong L, Hidalgo GE, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172: 1308-14.
32. Chen G, Wang X, Yu J, et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007; 67: 3461-7.
33. Cekaite L, Hovig E, Sioud M. Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses. Methods Mol Biol 2007; 360: 335-48.
34. Gao WM, Kuick R, Orchekowski RP, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005; 5: 110.
35. Caron M, Choquet-Kastylevsky G, Joubert-Caron R. Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery. Mol Cell Proteomics 2007; 6: 1115-22.
36. Gunawardana CG, Diamandis EP. High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 2007; 249: 110-9.
37. Chen YT. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J Sci Am 2000; 6 (Suppl 3): S208-S217.
38. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-3.
39. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
40. Chen YT, Old LJ. Cancer-testis antigens: targets for cancer immunotherapy. Cancer J Sci Am 1999; 5: 16-7.
41. Jager E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999; 84: 506-10.
42. Mizukami M, Hanagiri T, Baba T, et al. Identification of tumor associated antigens recognized by IgG from tumor-infiltrating B cells of lung cancer: correlation between Ab titer of the patient's sera and the clinical course. Cancer Sci 2005; 96: 882-8.
43. Gerhardt A, Usener D, Keese M, Sturm J, Schadendorf D, Eichmuller S. Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett 2004; 208: 197-206.
44. Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999; 96: 1-4.
45. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds [see comments]. Science 1996; 273: 104-6.
46. Watanabe N, Arase H, Onodera M, Ohashi PS, Saito T. The quantity of TCR signal determines positive selection and lineage commitment of T cells. J Immunol 2000; 165: 6252-61.
47. Brass N, Racz A, Bauer C, Heckel D, Sybrecht G, Meese E. Role of amplified genes in the production of autoantibodies. Blood 1999; 93: 2158-66.
48. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66: 6-9.
49. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 2005; 11: 1521-6.
50. Line A, Stengrevics A, Slucka Z, Li G, Jankevics F, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002; 86: 1824-30.
51. Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 2002; 51: 574-82.
52. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005; 42: 342-57.
53. Yang F, Chen IH, Xiong Z, Yan Y, Wang H, Yang XF. Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens. Clin Immunol 2006; 121: 121-33.
54. Yan Y, Phan L, Yang F, et al. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol 2004; 172: 651-60.
55. Nakagawa K, Noguchi Y, Uenaka A, et al. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005; 11: 5496-503.
56. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res 2003; 31: 5635-43.
57. Wang Z, Lo HS, Yang H, et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 2003; 63: 655-7.
58. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001; 293: 251-3.
59. Gad M, Jensen T, Gagne R, et al. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Eur J Immunol 2003; 33: 1624-32.
60. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004; 427: 252-6.
61. Ostankovitch M, Robila V, Engelhard VH. Regulated folding of tyrosinase in the endoplasmic reticulum demonstrates that misfolded full-length proteins are efficient substrates far class I processing and presentation. J Immunol 2005; 174: 2544-51.
62. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001; 98: 12659-64.
63. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1 definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
64. Walton SM, Gerlinger M, de la RO, et al. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol 2006; 177: 8212-8.
65. Jager D, Karbach J, Pauligk C, et al. Humoral and cellular immune responses against the breast cancer antigen NY-BR-1 definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005; 5: 11.
66. Di MF, Bronzi G, Scanlan MJ, et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004; 109: 909-18.
67. Gnjatic S, Atanackovic D, Jager E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 8862-7.
68. Nagata Y, Ono S, Matsuo M, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 2002; 99: 10629-34.
69. Coughlan S, Harkiss GD, Hopkins J. Enhanced proliferation of CD4+ T cells induced by dendritic cells following antigen uptake in the presence of specific antibody. Vet Immunol Immunopathol 1996; 49: 321-30.
70. Berlyn KA, Schultes B, Leveugle B, Naujaim AA. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 2001; 101: 276-83.
71. Nishikawa H, Tanida K, Ikeda H, et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA 2001; 98: 14571-6.
72. Nishikawa H, Kato T, Tanida K, et al. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003; 100: 10902-6.
73. Nishikawa H, Kato T, Tawara I, et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med 2005; 201: 681-6.
74. Nishikawa H, Kato T, Tawara I, et al. IFN-gamma controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J Immunol 2005; 175: 4433-40.
75. Ehlken H, Schadendorf D, Eichmuller S. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 2004; 108: 307-13.
76. Gogas H, Ioannovich J, Dafhi U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
77. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 2006; 144: 41-7.
78. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
79. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
80. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
81. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005.
82. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-62.
83. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3: 10.
84. Wang Y, Wu XJ, Zhao AL, et al. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. Cancer Immun 2004; 4: 11.
85. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12: 764-71.
86. Akcakanat A, Kanda T, Koyama Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54: 95-100.
87. Cawley HM, Meltzer SJ, De BV, et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 1998; 115: 19-27.
88. Trivers GE, De BV, Cawley HL, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996; 2: 1767-75.
89. Wollenberg B, Jan NV, Pitzke P, Reiter W, Stieber P. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Anticancer Res 1997; 17: 413-8.
90. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998; 4: 2147-52.
91. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-73.
92. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006; 1: 513-9.
93. Spisek R, Kukreja A, Chen LC, et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 2007; 204: 831-40.